Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK3 | Q13188 | 1/20 | 0.82 |
| ▸ | STK4 | Q13043 | 5/20 | 0.80 |
| ▸ | EGFR | P00533 | 14/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22419649 | 0.93 | STK4 (0.79) | STK3STK4EGFRERBB2 | |
| SCHEMBL4965102 | 0.92 | EGFR (0.81) | STK3STK4EGFRERBB2 | |
| SCHEMBL22847992 | 0.91 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL33532011 | 0.90 | STK3 (1.00) | STK3STK4EGFRERBB2 | |
| SCHEMBL2384641 | 0.90 | STK3 (1.00) | STK3STK4EGFRERBB2 | |
| SCHEMBL5496956 | 0.89 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL5496959 | 0.89 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL22419619 | 0.89 | STK4 (0.82) | STK3STK4EGFRERBB2 | |
| SCHEMBL29515007 | 0.89 | STK4 (0.82) | STK3STK4EGFRERBB2 | |
| SCHEMBL22419648 | 0.89 | STK4 (1.00) | STK3STK4EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427560-B2 | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210061784-A1 | COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1 | UNIVERSITÄT BREMEN (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10774068-B2 | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-09-15 | — | — | US | disclosed |
| US-7982043-B2 | Protein tyrosine kinase enzyme inhibitors | WYETH LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7399865-B2 | such as (E)-N-{4-[4-(benzyloxy)-3-chloroanilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide used as antineoplastic agents, or inhibitors of the HER-2 gene or proteins and epidermal growth factor receptor enzymes | WYETH (US) | 2008-07-15 | — | — | US | disclosed |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| EP-1670473-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034955-A1 | SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028443-A2 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | WYETH A CORPORATION OF THE STATE OF DELAWARE, USA (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | WYETH (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061784-A1 | COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1 | TESK2, TESK1, PRKACB | STK3 456/4885STK4 852/4885EGFR 3953/4885 |
| US-20080319011-A1 | PROTEIN TYROSINE KINASE ENZYME INHIBITORS | ABL1, ERBB2, RET | STK3 138/4885STK4 168/4885EGFR 6/4885 |
| US-20050059678-A1 | Protein tyrosine kinase enzyme inhibitors | ABL1, ERBB2, RET | STK3 138/4885STK4 168/4885EGFR 6/4885 |
| US-20060270668-A1 | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof | HCCS, CYP3A7, QPCT | STK3 444/4885STK4 838/4885EGFR 4068/4885 |
| US-11427560-B2 | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 | TESK2, TESK1, PRKACB | STK3 456/4885STK4 852/4885EGFR 3953/4885 |
| US-10774068-B2 | Composition and methods for inhibiting mammalian sterile 20-like kinase 1 | TESK2, TESK1, PRKACB | STK3 456/4885STK4 852/4885EGFR 3953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.